UCB, a global biopharmaceutical company, today announced that 15 scholarships were awarded to people impacted by myasthenia gravis in the U.S. The UCB Myasthenia Gravis Scholarship™ exemplifies ...

Telitacicept is a dual-targeting agent that attaches to and blocks the effects of 2 key signaling proteins, B-lymphocyte ...

OTTAWA — Established treatments such as thymectomy and steroids remain mainstays in the management of myasthenia gravis (MG), according to a presentation at the Canadian Neurological Sciences ...

The FDA has approved Alexion's Soliris for use in patients with treatment resistant generalised Myasthenia gravis (gMG), making it the first new therapy for the condition in 60 years.

About Myasthenia Gravis. Myasthenia Gravis (MG) is a rare neurological disorder that severely impairs muscle movement and can lead to life-threatening complications.

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis ...

Myasthenia gravis, an immune-mediated neurologic disorder, has for the past century been treated effectively with various immunotherapies, ranging from thymectomy to approved targeted agents.1,2 Th ...